Early Terli

Giving terlipressin at lower creatinines (1.5-2.0) or within 12 hours of presentation (skipping the “albumin challenge”)

1. From the RCTs journals.lww.com/hepcomm/page...
2. Pilot trial doi.org/10.1007/s106...

#liversky

The QUASAR trial- guselkumab vs placebo in mod-severe UC

1️⃣Induction 200mg IV (0,4,8) or placebo

📗Maintenance 200mg SC q4w, 100mg SC q8w or placebo
Guselkumab better than placebo in all the outcomes

@thelancet.bsky.social

www.thelancet.com/journals/lan...

NEW Year-in-Review in #NatureReviewsGastroHep highlighting the key papers in #IBD in 2024

Biologic agents for IBD come of age as host–microbe interactions emerge
By Leolin Katsidzira & Benjamin Misselwitz
www.nature.com/articles/s41...

#IBDsky #GastroSky #Microsky 🧪

It's that time of the year again. In no particular order, I would like to share a few of #livertwitter in 2024 with #liversky

These could be original research, guidance statement, position paper or editorial. This is def not an inclusive list. Feel free to add to the 🧵

Excellent overview on personalized #IBD therapy for #crohnsdisease complications by @MRegueiroMD at #AIBD2024. Take home point: failure of medical therapy is an adverse event that could be serious!

🎉The latest IBD-Ell newsletter is out!
- New trials added 🌟We've far surpassed 400 summarized trials🌟
- New guidelines
- New cheat sheet with lymphocyte trafficking and anti-integrins
Thanks for following along! www.ibd-eii.com
Subscribe for free anytime 📩
#IBD

The wheel of life !

Primary sclerosing cholangitis.

#LiverSky #IBDSky

It's my favourite time of year - Year in Review time - and the first batch have landed online in NatRevGastroHep. These short articles summarise the top research in 2024 and key advances in a range of topics @natureportfolio.bsky.social
www.nature.com/nrgastro/rev...

#GastroSky #Liversky #Microsky

The AGA’s first-ever living guideline formoderate-to-severe #UlcerativeColitis led by S Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social , @ashwinmdibd, @EdwardLoftus2 and myself prioritizes early use of advanced txs over a step-up approach.

ow.ly/t2Ru50UahEi

Periappendiceal red patch in ulcerative colitis

- aka caecal patch, appendiceal orifice inflammation
- a curious finding
- usually does not influence management
- does not mean that the disease is extensive

#IBDSky

Vedolizumab to prevent postoperative recurrence of Crohn's disease (the REPREVIO RCT)

"Vedolizumab prevented postoperative recurrence of CD & should be considered as a prophylactic treatment in individuals with risk factors for recurrence."

www.thelancet.com/journals/lan...

#GastroSky #IBDSky

We cannot eat 💴

CAVALRY trial:
Open-label RCT of Child B/C cirrhosis pts with high risk varices.
- combination of carvedilol + banding reduces the risk of bleeding at 12 months
- reducing portal pressures + eradicating varices have additive effects without causing harm

#LiverSky #MedSky

PREDICT-UC

Multicenter open-label RCT in acute severe ulcerative colitis.
Higher doses of IFX did not result in better clinical response by days 7/14, nor colectomy rates by 3 mths.
Maintenance dosing for intensified/accelerated dosing groups limited by local restrictions.

#IBDSky

First post here !!

This is the most important resource for people interested in inflammatory bowel disease

ibd-eii.com

It is run by Beatriz Gros

She is not on BlueSky yet. Please peer pressure her